The approved immune thrombocytopenia (ITP) treatment Doptelet (avatrombopag) may be able to be repurposed to treat certain bone…
Marisa Wexler MS
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler MS
IMMUNE THROMBOCYTOPENIA
NewsCell therapy QT-019B shows strong response rate in hard-to-treat ITP
Use of the experimental cell therapy QT-019B showed promise for people with treatment-resistant immune thrombocytopenia (ITP) in early clinical…
VON WILLEBRAND DISEASE
NewsOver-the-ear device eases heavy menstrual bleeding, pain in trial
Electrical stimulation of nerves that control automatic bodily functions, administered twice daily through a device worn over the ear, may…
IMMUNE THROMBOCYTOPENIA
NewsScientists zero in on 2 proteins as potential treatment targets in ITP
Scientists in China have discovered that the proteins RNF5 and DNAJC21 — the latter encoded by the DNAJC21 gene —…
IMMUNE THROMBOCYTOPENIA
NewsNew ‘needle in the haystack’ antibody-based therapies target ITP
Researchers have developed two novel antibody-based therapies that may be used to treat antibody-mediated autoimmune diseases such as immune…
IMMUNE THROMBOCYTOPENIA
NewsWayrilz recommended for approval in Europe to treat ITP
An arm of the European Medicines Agency (EMA) is recommending that Wayrilz (rilzabrutinib) be approved to treat adults with…
VON WILLEBRAND DISEASE
NewsPreclinical study points to new way to treat VWD type 1
Researchers created an experimental treatment for von Willebrand disease (VWD) type 1 that aims to stabilize the protein whose…
THROMBOTIC THROMBOCYTOPENIC PURPURA
NewsSwitching to Adzynma slashes hospital stays in congenital TTP
Switching from treatment with fresh frozen plasma (FFP) to Adzynma (ADAMTS13, recombinant-krhn) can help people with congenital thrombotic thrombocytopenic…
VON WILLEBRAND DISEASE
NewsStar Therapeutics raises $125M to advance bleeding treatment
Star Therapeutics has raised $125 million to support the development of VGA039, a treatment for von Willebrand disease…
IMMUNE THROMBOCYTOPENIA
NewsLow-dose drug combo may be effective treatment for ITP
Combining low-dose eltrombopag with reduced-dose prednisone may be an effective approach for controlling immune thrombocytopenia (ITP) while minimizing the…